Patenting Animal Genetic Inventions The Ethics of Patenting Animal Genetic Inventions - NCCR PhD Workshop 2007 - Michelangelo Temmerman.

Slides:



Advertisements
Similar presentations
Chuck Schmal Patent & Trademark Attorney
Advertisements

WIPO Life Science Symposium on IP and Bioethics - Felix AddorSeptember 4, Dr. Felix Addor Deputy Director General, Swiss Federal Institute of Intellectual.
Ethical aspects and Patents in Lifescience Peter R. Thomsen Manager Global IP Litigation, Corporate Intellectual Property, Novartis WIPO symposium on IP.
Ato221 - WIPO-UPOV Symp. on IPRs in Plant Biotech., Gva, Article 27.3(b) of the TRIPS Agreement 3.Members may also exclude from patentability:
WIPO-UPOV SYMPOSIUM October 25, 2002UPOV. Rolf Jördens Vice Secretary-General UPOV LEGAL AND TECHNOLOGICAL DEVELOPMENTS LEADING TO THIS SYMPOSIUM: UPOVS.
Agrobiodiversity and Intellectual Property Rights: Selected Issues under the FAO International Treaty on Plant Genetic Resources for Food and Agriculture.
Institut der beim Europäischen Patentamt zugelassenen Vertreter Institute of Professional Representatives before the European Patent Office Institut des.
The New Israeli Copyright Act A Case-Study in Reverse Comparative Law.
Industrial Property the Patent system
Intellectual Property Rights (IPR)
LATEST DEVELOPMENTS IN BIOTECH PATENTS Carine van den Brink 18 April 2012.
Selected Cases on Patents and Biotechnology WIPO-UKRAINE SUMMER SCHOOL ON INTELLECTUAL PROPERTY – JULY 2011.
The transgenic or genetically modified organisms are a number of plants or animals that have been handled in laboratories. This manipulation is to add.
Interface between patent and sui generis systems of protection of plant varieties The 1978 UPOV Act does not allow both systems to be applied to the same.
Convention on Biological Diversity, Traditional Knowledge and the TRIPS Agreement Yovana Reyes Tagle University of Helsinki.
Patent protection of biotechnology inventions in Brazil Leonor Galvão de Botton, Ph.D. AIPLA Webinar June 27, 2013.
The patentability of biotechnological inventions: The European Commission’s second 16c report Paul Van den Bulck Partner at Ulys Law Firm (Brussels) Lecturer.
Health Law and Bioethics FDUNL 2.Nd Semester Prof. Helena Pereira de Melo 2010/2011 Joana Magalhães n.º
Ownership and distribution Ethical issues in patenting Pr Samia Hurst Institute for Biomedical Ethics University of Geneva Medical School.
1 Standing Committee on the Law of Patents (SCP) A United States Perspective Stephen G. Kunin Deputy Commissioner for Patent Examination Policy United.
Ethics of Patents in Stem Cell Research
The European legal framework for patentability and regulation of stem cells : focus on Germany, Spain and France Paul Van den Bulck Partner at Ulys Law.
20th October 2006 Latest evolutions in “software patents” and “biotech patents” by Paul Van den Bulck Partner ULYS Law Firm (Brussels-Paris) Lecturer at.
Ethics and Patents Gwilym Roberts Partner, Kilburn & Strode Kilburn & Strode LLP | 20 Red Lion Street | London | WC1R 4PJ | United Kingom T: +44.
Aurora Plomer, BA, MA, LLB, PhD Professor of Law & Bioethics Director of SIBLE University of Sheffield
TRIPS obligations and flexibilities regarding life forms and plant varieties, and the effects of FTAs By Chee Yoke Ling Third World Network Asian Regional.
Health Law and Bioethics Prof. Dra. Helena Pereira de Melo 2011/ de Março de 2012 Pedro Marques Gaspar Aluno n.º
Heli Pihlajamaa June 2015Director Patent Law Update on electronic tools of the EPO – notification, filing and fee payment.
The patentability of human pluripotent embryonic stem cells and stem cell lines Paul Van den Bulck Partner at Ulys Law Firm (Brussels) Lecturer at the.
Rodolphe Bauer, Frédéric Dedek, Gareth Jenkins, Cristina Margarido
The Case of Myriad Genetics (Vs. an array of National Government Funded European Union Research Institutes) Amir Zaher UC Berkeley, Senior Department of.
Patent Eligibility in Europe Colo(u)ring the Gre/ay Areas Ilya Kazi and Andrew Bentham On behalf of International Liaison Committee Supporting logos to.
Biotechnology Assignment 7 Patent Law. Case study 1 –Federal Supreme Court Germany (Bundesgerichshof), 27 March 1969 (Red Dove), IIC, 1970, 136 –Answer.
Patenting Stem Cells of Human Origin ATRIP Conference, Tokyo, 2003 In the wake of the Commission’s first report on the 1998 Directive on the legal protection.
Biotech Inventions in Latin America Argentina Ignacio Sánchez Echagüe Marval, O’Farrell & Mairal.
Page 1 IOP Genomics Workshop Patents and Patenting Biotech Inventions Annemieke Breukink, Ph.D. September 8th, 2009.
Review of the New Substances Notification Regulations (Organisms) – an Update CCAC National Workshop 2010 Crowne Plaza Hotel, Ottawa, ON Presented by:
Heli PihlajamaaLondon, Director Patent Law (5.2.1) Clarity - Article 84 EPC.
Introduction to Patents Anatomy of a Patent & Procedures for Getting a Patent Margaret Hartnett Commercialisation & IP Manager University.
Session 6 : An Introduction to the TRIPS Agreement UPOV, 1978 and 1991 and WIPO- Administered Treaties.
Dr. Marie Talnack, Director, TechnologyTransfer Office and Industry Clinic.
NCCR International Trade NCCR IP9 WORKSHOP 28 th March “Prior Informed Consent in European Patent Law: Overview and Options” - Michelangelo R.P.
21 April 2005Felix Addor - Disclosure Requirement1 Felix Addor Head of the Swiss Delegation to the WTO/TRIPS-Council Deputy Director General Swiss Federal.
Case 428/08 Monsanto v Cefetra e.a THE FUTURE OF BIOTECH PATENT PROTECTION IN EUROPE What every biotech patent practitioner should know John J. Allen.
© J. Straus Patenting of Genes and Life Forms, and the impact of Patenting on Upstream Science Joseph Straus, Munich WIPO Open Forum on the Draft.
NCCR International Trade NCCR IP9 WORKSHOP 17 th May 2006 Patentability of Life Forms By Michelangelo Temmerman.
SM © 2012 Patterson Thuente Christensen Pedersen, P.A., some rights reserved - DISCLAIMER: This presentation and any information.
CUTS International Capacity Building Training Programme on Advance IPR, WTO-Related Issues and Patent Writing April 28-May 02, 2008, Jaipur TRIPS – Article.
Protection of biotechnology innovations in Brazil Leonor Galvão de Botton, Ph.D. AIPLA Spring Meeting May, 2013.
© 2008 International Intellectual Property June 16, 2009 Class 2 Introduction to Patents.
PATENTS, INTEGRATED CIRCUITS, AND INDUSTRIAL DESIGNS Presented By: Navdeep World Trade Organization.
Law and Policy of Relevance for the Management of Plant Genetic Resources Objectives of Session 6 To discuss the meaning of sui generis protection.
15-16 May 2007Geertrui Van OverwalleEUPACO One size fits all? How unitary is the present European patent system? Geertrui Van Overwalle Centre for Intellectual.
International Intellectual Property Prof. Manheim Spring, 2007 Biotechnology Patents Copyright © 2007.
Introduction The Patentability of Human Genes Is patenting human genes moral? Should it be legal? Should there be international intervention?
Patent Review Overview Summary of different types of Intellectual Property What is a patent? Why would you want one? What are the requirements for patentability?
VISHAAL HARISARAN Intellectual Property Rights in Animal Breeding and Genetics.
Contact: Serving society Stimulating innovation Supporting legislation Joint Research Centre (JRC) 15 July 2013.
Funding and patentability of stem cell research in the European Union - A critical legal review of European legislation Dr. Malene Rowlandson, University.
International Intellectual Property Profs. Atik and Manheim Fall, 2006 Biotechnology Patents.
Ip4inno 1 Content of the module IP for the creative industries Patented computer-implemented inventions Software Biotechnological inventions.
AIPLA Spring Meeting, Houston Texas
Overview of presentation
Intellectual Property & Contemporary Issues of Biotechnology Law
Institutional support IN development of Transferable Skills
Breeding bulls.
Susy Frankel Victoria University of Wellington New Zealand
Introduction to the Biological Level of Analysis (BLOA)
TRIPS Art. 27.3(b) and Agriculture
Influence of AI creations on the IP rules
Presentation transcript:

Patenting Animal Genetic Inventions The Ethics of Patenting Animal Genetic Inventions - NCCR PhD Workshop Michelangelo Temmerman

Introduction What is a Patent? Patentability of Animal Biological Material: –Article 27 TRIPs Agreement –European Patent Office –United States –Canada

Animal Gene Sequences Isolation into laboratory form + function = Patentable Patent on information or patent on a biological substance? Scope of gene sequence patents: limited to laboratory form or extending to the organisms in which they are incorporated?

Ordre Public & Morality European concept: inexistent in the US and Canada: Article 53 (a) EPC, Shall not be patentable: “inventions the publication or exploitation of which would be contrary to “ordre public” or morality, provided that the exploitation shall not be deemed to be so contrary merely because it is prohibited by law or regulation in some or all of the Contracting States”. (emphasis added) EPO: Balancing test evaluating the ‘likely’ suffering of animals v. ‘any’ medical benefit (Cf. Oncomouse) Ordre Public?

Questions Is the ordre public/morality concept relevant anyway given the (limited) nature of patents? Is the (commercial) exploitation of (certain) transgenic animals immoral? Is the (commercial) exploitation of (certain) transgenic animals contrary to the ordre public?